Andong Huang - Oct 1, 2025 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role: Director
Signature: /s/Lawrence A. Kenyon, Attorney-in-Fact
Stock symbol: OTLK
Transactions as of: Oct 1, 2025
Transactions value $: $0
Form type: 4
Date filed: 10/3/2025, 08:37 PM
Previous filing: Oct 3, 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Huang Andong	Director	C/O OUTLOOK THERAPEUTICS, INC., 111 S. WOOD AVE, UNIT #100, ISELIN	/s/Lawrence A. Kenyon, Attorney-in-Fact	2025-10-03	0001815678

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OTLK	Stock Option (Right to Buy)	Award	$0	+287K		$0.00	287K	Oct 1, 2025	Common Stock	287K	$1.04	Direct	F1
transaction	OTLK	Stock Option (Right to Buy)	Award	$0	+53.3K		$0.00	53.3K	Oct 3, 2025	Common Stock	53.3K	$1.06	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
F2	The options were granted under the 2024 Plan in lieu of $50,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

Content

This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.

The options were granted under the 2024 Plan in lieu of $50,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.